Paul J. Shami
Professor
Department of Hematology
Huntsman Cancer Institute
United States of America
Biography
Dr. Paul Shami is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah and is a Member and Clinical Investigator at the University’s Huntsman Cancer Institute (HCI). Dr. Shami also holds an Adjunct appointment as a Professor of Pharaceutics and Pharmaceutical Chemistry at the University of Utah. He is Board Certified in Hematology and Medical Oncology. Dr. Shami oversees leukemia clinical trials at Hunstman Cancer Institute, where he has established the most comprehensive leukemia clinical trials program in the Intermountain West. Because of his expertise and national recognition in the treatment of blood cancers, he serves or has served on the Acute Myeloid Leukemia, Chronic Myelogenous Leukemia and Myelodysplastic Syndrome panels of the National Cancer Center Network (NCCN). These NCCN panels develop guidelines that are followed nationally and internationally for the treatment of cancer.
Research Interest
Leukemia, Myeloid Nitric Oxide Nitric Oxide Donors Glutathione Transferase Acute Myeloid Leukemia (AML) Drug Development Myelodysplastic Syndromes
Publications
-
Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, ODonnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C (2015). Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw, 13(3), 261-72.
-
Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F (2015). REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol, 168(6), 796-805.
-
Zhang R, Yang J, Zhou Y, Shami PJ, Kopecek J (2016). N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia. Macromol Biosci, 16(1), 121-128.
